Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 4

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 4
---
 implemented with retrospective effect. Comparative figures for prior periods have been restated accordingly.

#### Conference Call
Genmab will hold a conference call to discuss the results for the first half of 2025 today, Thursday, August 7, at 6:00 pm CEST, 5:00 pm BST or 12:00 pm EDT. To join the call please use the below registration link. Registered participants will receive an email with a link to access dial-in information as well as a unique personal PIN: https://register-conf.media-server.com/register/BI28443f2e11ba47dba51e3a14d0c7a98f . A live and archived webcast of the call and relevant slides will be available at www.genmab.com/investor-relations .

#### Contact
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs

T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations

T: +45 3377 9558; E: acn@genmab.com

*sBLA = supplemental Biologics License Application, FDA = U.S. Food and Drug Administration, R 2 = rituximab and lenalidomide, FL = follicular lymphoma, ASCO = American Society of Clinical Oncology

| Genmab A/S            
 Carl Jacobsens Vej 30 
 2500 Valby, Denmark   |     | Tel: +45 7020 2728 
 www.genmab.com     |     | Company Announcement no. 40 
 Page 2/44                   
 CVR no. 2102 3884           |

#### Interim Report for the First Half of 2025
| CONTENTS                                                    |     |    |
| MANAGEMENT’S REVIEW                                         |     |    |
| CONSOLIDATED KEY FIGURES                                    |     |  4 |
| OUTLOOK                                                     |     |  5 |
| PRODUCT PIPELINEAND TECHNOLOGY PROGRESS FIRST HALF OF 2025  |     |  6 |
| SIGNIFICANT RISKS AND UNCERTAINTIES                         |     | 15 |
| FINANCIAL REVIEW                                            |     | 16 |
| CONDENSED CONSOLIDATED FINANCIAL STATEMENTS                 |     | 24 |
| NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS    |